Medicines for Malaria Venture (MMV) is a not-for-profit public-private partnership aimed at reducing the global burden of malaria by discovery, development and delivery of new, effective and affordable antimalarial drugs. To help celebrate its 15th anniversary, MMV has launched the production of a series of short films highlighting the work involved in its most exciting projects.

One of the short films is about the ongoing development of MMV048, a novel antimalarial compound belonging to the aminopyridine class. The film explains that, in combination with a partner drug, MMV048 has the potential to become a new child-friendly treatment for uncomplicated malaria that could be given as one single dose, completing the treatment in just one day instead of the current three days.